Evidence map›Paper›PMID 33101208›Full record

SynthesisFrontiers in endocrinology2020

Primary Aldosteronism and Bone Metabolism: A Systematic Review and Meta-Analysis.

Shaomin Shi, Chunyan Lu, Haoming Tian, Yan Ren, Tao Chen

Open access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Frontiers in endocrinology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Integrated morphological and transcriptomic analysis of bone disorders in aldosterone-salt hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Article
  4. Review
  5. Observational
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Hip fractures in patients with primary aldosteronism - a Swedish nationwide study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024
    Article
  14. Article
  15. Proteomic Analysis Based on TMT Regarding the Therapeutic Action ofCombinatorial chemistry & high throughput screening · 2024
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Shaomin ShiDepartment of Endocrinology and Metabolism, Adrenal Center, West China Hospital of Sichuan University, Chengdu, China.
Chunyan LuDepartment of Endocrinology and Metabolism, Adrenal Center, West China Hospital of Sichuan University, Chengdu, China.
Haoming TianDepartment of Endocrinology and Metabolism, Adrenal Center, West China Hospital of Sichuan University, Chengdu, China.
Yan RenDepartment of Endocrinology and Metabolism, Adrenal Center, West China Hospital of Sichuan University, Chengdu, China.
Tao ChenDepartment of Endocrinology and Metabolism, Adrenal Center, West China Hospital of Sichuan University, Chengdu, China.
Sichuan University · CNWest China Hospital of Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Currently, increasing evidence shows that excess aldosterone may have an impact on bone health, and primary aldosteronism (PA) may be a secondary cause of osteoporosis. This problem is worthy of attention because secondary osteoporosis is always potentially reversible, which affects the selection of treatment for PA to some extent. The present systematic review will assess and summarize the available data regarding the relationship between PA and osteoporosis. Methods: Pubmed and Embase were searched for clinical trials related to the association between PA and bone metabolism. The results were limited to full-text articles published in English, without restrictions for the publication time. The quality of clinical trials was appraised, and the data were extracted. Biochemical parameters of bone turnover in PA patients were assessed using random-effect meta-analysis. Descriptive analysis was performed for other parameters, for data is insufficient. Results: A final total of 15 articles were included in this review. The meta-analysis of six studies showed that subjects with PA had higher serum PTH levels ( Conclusions: PA may be a secondary cause of osteoporosis and is associated with an increased risk of bone fracture. The clarification of the relationships between PA and bone metabolism requires additional prospective randomized controlled studies in a large sample.

Indexed as

AldosteroneBone and BonesBone DensityFractures, BoneHumansHyperaldosteronismOsteoporosisParathyroid HormoneSpironolactoneAldosteroneParathyroid HormoneSpironolactonebone metabolismfractureosteoporosisprimary aldosteronismsystematic review

Identifiers

PMID33101208
PMCPMC7546890
OpenAlexW3088567765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.